KTTA/ 11/13/2026 · 11:11 AM Pasithea Reports Substantial Tumor Shrinkage With PAS-004 in Early NF1 Study, FDA Clears Phase 2 Early results show PAS-004 reduced neurofibroma size in all evaluated NF1 patients.
